---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-002100"
form_type: "8-K"
ticker: "PLX"
cik: "0001006281"
company_name: "Protalix BioTherapeutics, Inc."
filed_at: "2023-02-27T23:59:59+00:00"
generated_at: "2026-06-18T23:10:56.779224+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Protalix FY2022 net loss narrows to $14.9M; CHMP positive opinion for PRX-102; FDA PDUFA May 9

## Summary
- Net loss of $14.9M ($0.31/share) vs $27.6M ($0.62/share) in FY2021; revenue from goods up 51% to $25.3M.
- EMA CHMP adopted positive opinion recommending marketing authorization for PRX-102 (pegunigalsidase alfa) for Fabry disease; EC decision expected May 2023.
- FDA accepted resubmitted BLA for PRX-102 with PDUFA action date of May 9, 2023; milestone payment from Chiesi if approved.
- Cash and equivalents $22.2M at Dec 31, 2022; voluntary delisting from Tel Aviv Stock Exchange effective March 22, 2023.

## SEC filing metadata
- accession: 0001558370-23-002100
- form_type: 8-K
- ticker: PLX
- cik: 0001006281
- company_name: Protalix BioTherapeutics, Inc.
- filed_at: 2023-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006281/000155837023002100/0001558370-23-002100-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006281/000155837023002100/plx-20230227x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-002100
- JSON: https://secwatch.observer/filing/0001558370-23-002100.json
- Plain text: https://secwatch.observer/filing/0001558370-23-002100.txt

## Key facts
- Earnings Releases
  Protalix BioTherapeutics, Inc. reported the fiscal year ended December 31, 2022 results: revenue $25.3 million.
  - Period: the fiscal year ended December 31, 2022
  - Revenue: $25.3 million
  - Result: reported results
  source text: Committee. Financial Results For the year ended December 31, 2022, compared to the year ended December 31, 2021 ● The Company recorded revenues from selling goods of $25.3 million for the year ended December 31, 2022, an increase of $8.6 million, or 51%, compared to revenues of $16.7 million for the year ended December 31, 2021. The increase resulted from
  evidence_url: https://www.sec.gov/Archives/edgar/data/1006281/000155837023002100/0001558370-23-002100-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.